Actuate Therapeutics (NASDAQ:ACTU) on Saturday introduced encouraging outcomes from a Part 2 scientific trial testing its experimental most cancers drug, elraglusib, together with normal chemotherapy in sufferers with superior pancreatic most cancers.
The findings, shared Saturday on the 2025 American Society of
